Tseleni-Balafouta S - Search Results

1

Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.

Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA, Mitsiades N. Poulaki V, et al. J Clin Endocrinol Metab. 2003 Nov;88(11):5392-8. doi: 10.1210/jc.2003-030389. J Clin Endocrinol Metab. 2003. PMID: 14602779

2

Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N. Poulaki V, et al. Am J Pathol. 2002 Aug;161(2):643-54. doi: 10.1016/S0002-9440(10)64220-4. Am J Pathol. 2002. PMID: 12163389 Free PMC article.

3

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N. Mitsiades CS, et al. J Clin Endocrinol Metab. 2006 Sep;91(9):3662-6. doi: 10.1210/jc.2006-0055. Epub 2006 Jul 5. J Clin Endocrinol Metab. 2006. PMID: 16822827

4

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N. Mitsiades CS, et al. J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21. doi: 10.1210/jc.2005-2472. Epub 2006 Jul 18. J Clin Endocrinol Metab. 2006. PMID: 16849420

5

Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.

Poulaki V, Mitsiades CS, McMullan C, Fanourakis G, Negri J, Goudopoulou A, Halikias IX, Voutsinas G, Tseleni-Balafouta S, Miller JW, Mitsiades N. Poulaki V, et al. Invest Ophthalmol Vis Sci. 2005 Jan;46(1):358-66. doi: 10.1167/iovs.04-0324. Invest Ophthalmol Vis Sci. 2005. PMID: 15623796

6

Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.

Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, Voutsinas G, Tseleni-Balafouta S, Mitsiades N. Mitsiades CS, et al. Clin Cancer Res. 2006 Jun 15;12(12):3705-12. doi: 10.1158/1078-0432.CCR-05-2493. Clin Cancer Res. 2006. PMID: 16778096

7

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.

Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N. Mitsiades CS, et al. Mol Cancer Ther. 2007 Mar;6(3):1070-8. doi: 10.1158/1535-7163.MCT-06-0449. Mol Cancer Ther. 2007. PMID: 17363500

8

Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.

Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta ST, Kotoula V, Koutras DA, Tsokos M. Mitsiades N, et al. J Clin Endocrinol Metab. 1999 Aug;84(8):2924-32. doi: 10.1210/jcem.84.8.5917. J Clin Endocrinol Metab. 1999. PMID: 10443700

9

Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis.

Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-Balafouta S, Koutras DA, Tsokos M. Mitsiades N, et al. J Clin Endocrinol Metab. 1998 Jun;83(6):2199-203. doi: 10.1210/jcem.83.6.4853. J Clin Endocrinol Metab. 1998. PMID: 9626160

10

Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.

Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Mitsiades N, et al. Cancer Res. 2000 Aug 1;60(15):4122-9. Cancer Res. 2000. PMID: 10945619

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters